Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment

Reuters01-20

Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment

Ascletis Pharma Inc. has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application $(IND)$ to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN66622) on January 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604317195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604317195","market":"fut","top_or_hot":-1,"title":"Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN66622) on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-20 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN66622) on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5f9lyN:1","article_id":"2604317195","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604317195","pubTimestamp":1768899651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application  to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01672":"歌礼制药-B","BK1515":"抗疫概念","BK1574":"生物医药B类股"},"translate_title":"歌礼推出用于肥胖治疗的每月一次的强效三联激动剂ASC37","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment\n    \n\nAscletis Pharma Inc. has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application $(IND)$ to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN66622) on January 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604317195","isCrawlerRequest":true}